The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheimer's Disease (AD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Simvastatin's Potential Role in Therapy

NCT00486044

Alzheimer Disease

COMPLETED PHASE2

Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease

NCT01864655

Alzheimer's Disease

COMPLETED PHASE1

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

NCT00939822

Alzheimer's Disease

COMPLETED PHASE2

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

NCT00004845

Alzheimer Disease

COMPLETED PHASE2/PHASE3

Lipitor as a Treatment for Alzheimer's Disease

NCT00024531

Alzheimer Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is increasing evidence that nonsteroidal and cholesterol lowering medications may be associated with a delay in the onset of Alzheimer's disease (AD). There is separate evidence that beta-amyloid(1-42) is involved in the pathophysiology of AD and levels of beta-amyloid(1-42) in the cerebrospinal fluid (CSF) of AD patients are significantly lower than that found in controls. It has been suggested that these standard medications may have indirect effects that alter the normal course of AD, but there is no data to directly support this contention in humans. Based on previous work, it is our hypothesis that CSF beta-amyloid(1-42) levels may serve as an early biomarker of AD. Any pharmacological induced change in CSF beta-amyloid(1-42) might have profound implications for the eventual onset of illness. Therefore, the purpose of this study is to evaluate the short-term effects of two commonly prescribed nonsteroidal and cholesterol lowering medications, ibuprofen and lovastatin, on the levels of cerebrospinal fluid beta-amyloid(1-42) in a group of normal controls 'at risk' for developing AD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lovostatin

Intervention Type DRUG

Ibuprofen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Normal volunteer over the age of 18
2. Cognitively within normal limits at baseline evaluation
3. Previously evaluated in Protocol 95-M-0096
4. Women of child-bearing potential will be advised not to become pregnant during the treatment period

Exclusion Criteria

1. Known allergies to lovastatin or ibuprofen
2. Use of regular dosing of NSAID or statin during the previous month
3. Concurrent use of cyclosporine, itraconazole, ketoconazole, gemfibrozil, niacin, erythromycin, clarithromycin, HIV protease inhibitors or nefazodone because of possible drug interactions with lovastatin.
4. Women who are currently pregnant
5. Concurrent use of anticoagulants, aspirin, beta-adrenergic agents, cimetidine, digoxin and oral hypoglycemics because of possible drug interactions with ibuprofen.
6. Peptic ulcer disease by history
7. Autoimmune disease by history

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes